Study of VNRX-5133 in combination with a clinically validated broad spectrum beta-lactam for bacterial infections.

Trial Profile

Study of VNRX-5133 in combination with a clinically validated broad spectrum beta-lactam for bacterial infections.

Planning
Phase of Trial: Phase II/III

Latest Information Update: 19 Mar 2018

At a glance

  • Drugs VNRX 5133 (Primary) ; Beta-lactams
  • Indications Bacterial infections
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 19 Mar 2018 According to the VenatoRx Pharmaceuticals media release, company will start this pivotal registration trial in mid 2018
    • 08 Jan 2018 According to VenatoRx Pharmaceuticals pipeline, phase of this trial is phase II/III. (www.venatorx.com/pipeline/)
    • 08 Jan 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top